Calithera Biosciences (CALA) Reaches $14.75 52-Week High, Luminus Management Trimmed Teck Resources LTD (TCK) Holding By $40.24 Million

May 19, 2017 - By Linda Rogers

The stock of Calithera Biosciences Inc (NASDAQ:CALA) hit a new 52-week high and has $15.49 target or 5.00% above today’s $14.75 share price. The 8 months bullish chart indicates low risk for the $548.63M company. The 1-year high was reported on May, 19 by Barchart.com. If the $15.49 price target is reached, the company will be worth $27.43 million more. About 432,216 shares traded or 5.24% up from the average. Calithera Biosciences Inc (NASDAQ:CALA) has risen 6.00% since April 19, 2017 and is uptrending. It has by 0.00% the S&P500.

Luminus Management Llc decreased Teck Resources Ltd (TCK) stake by 65.48% reported in 2016Q4 SEC filing. Luminus Management Llc sold 2.01M shares as Teck Resources Ltd (TCK)’s stock 0.00%. The Luminus Management Llc holds 1.06 million shares with $21.25 million value, down from 3.07 million last quarter. Teck Resources Ltd now has $10.76B valuation. The stock rose 3.05% or $0.55 reaching $18.6. About 1.21 million shares traded. Teck Resources Ltd (USA) (NYSE:TCK) has risen 6.00% since April 19, 2017 and is uptrending. It has by 0.00% the S&P500.

Luminus Management Llc increased C H Robinson Worldwide Inc (NASDAQ:CHRW) stake by 440,375 shares to 979,375 valued at $71.75 million in 2016Q4. It also upped Kennametal Inc (NYSE:KMT) stake by 202,191 shares and now owns 684,191 shares. Ishares Tr (IWM) was raised too.

Among 19 analysts covering Teck Resources (NYSE:TCK), 9 have Buy rating, 2 Sell and 8 Hold. Therefore 47% are positive. Teck Resources had 33 analyst reports since July 23, 2015 according to SRatingsIntel. As per Tuesday, April 19, the company rating was maintained by JP Morgan. The rating was initiated by FBR Capital on Friday, September 18 with “Outperform”. The stock has “Market Perform” rating by FBR Capital on Thursday, April 21. The stock has “Sector Perform” rating by Scotia Capital on Thursday, July 23. The firm has “Market Perform” rating given on Friday, July 24 by Cowen & Co. As per Friday, October 16, the company rating was maintained by TheStreet. The stock has “Underperform” rating by CLSA on Tuesday, April 19. The stock of Teck Resources Ltd (USA) (NYSE:TECK) has “Buy” rating given on Monday, July 18 by Clarkson Platou. The stock has “Outperform” rating by RBC Capital Markets on Monday, October 17. Barclays Capital upgraded Teck Resources Ltd (USA) (NYSE:TECK) on Thursday, November 17 to “Overweight” rating.

Analysts await Teck Resources Ltd (USA) (NYSE:TECK) to report earnings on July, 27. TECK’s profit will be $561.44M for 4.79 P/E if the $0.97 EPS becomes a reality. After $0.88 actual EPS reported by Teck Resources Ltd (USA) for the previous quarter, Wall Street now forecasts 10.23% EPS growth.

Calithera Biosciences, Inc. is a clinical-stage pharmaceutical company. The company has market cap of $548.63 million. The Firm focuses on discovering and developing small molecule drugs directed against tumor and immune cell targets that control key metabolic pathways in the tumor microenvironment. It currently has negative earnings. It is engaged in developing agents that take advantage of the metabolic requirements of tumor cells and cancer-fighting immune cells, such as cytotoxic T-cells.